Task Force for Evidence Reports / Clinical Practice Guideline Committee for EBM, the Japan Society for Oriental Medicine

3. Blood Diseases including Anaemia

Reference

Nakamaoto H, Mimura T, Honda N. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis. *Hemodialysis International* 2008; 12: S9-14. CENTRAL ID: CN-00667345, Pubmed ID: 18837771

1. Objectives

To evaluate the efficacy and safety of juzentaihoto (十全大補湯) for erythropoietin-resistant anemia in patients on hemodialysis.

2. Design

Randomized controlled trial (RCT).

3. Setting

One university hospital and 1 general hospital, Japan.

4. Participants

Forty-two patients on hemodialysis with erythropoietin-resistant anemia.

5. Intervention

Arm 1: TSUMURA Juzentaihoto (十全大補湯) Extract Granules 2.5 g t.i.d. for 12 weeks (n=22). Arm 2: not treated with TSUMURA Juzentaihoto (十全大補湯) Extract Granules (n=20). Patients in the two groups were on the same dietary regimen and dialysis program.

6. Main outcome measures

Hemoglobin level.

7. Main results

While Hb level increased nonsignificantly from 8.3 ± 0.7 to 8.5 ± 0.5 g/dL in arm 2, it increased significantly from 8.4 ± 1.1 to 9.5 ± 1.3 g/dL in arm 1 (P=0.0272).

8. Conclusions

Treatment with TSUMURA Juzentaihoto Extract Granules is effective for erythropoietin-resistant anemia in patients on hemodialysis.

9. From Kampo medicine perspective None.

10. Safety assessment in the article

No adverse event (complication, abnormality in blood chemistry) was reported in the juzentaihoto group.

11. Abstractor's comments

This RCT was conducted in many patients with erythropoietin-resistant anemia and using a double-blind design. However, it is questionable that this trial was not placebo-controlled and no statistical analysis was mentioned. Given the decrease in serum C-reactive protein (CRP) level and negative correlation between serum CRP and Hb levels in the juzentaihoto group (and the absence of a decrease in serum CRP level and negative correlation in the non-treatment group), the authors assume that juzentaihoto may act, at least in part, as an anti-inflammatory agent. This is an interesting assumption that may suggest a basic research question.

12. Abstractor and date

Kogure T, 1 June 2010, 31 December 2013.